Navigating the Treatment Landscape to Improve Outcomes in Psoriasis: Essential Strategies for Proper Management

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2020 to August 1, 2021

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
AbbVie

Description:
Psoriasis is a complex, chronic, immune-mediated inflammatory disease that affects approximately 7 million of the population in the United States. Psoriasis is a periodic flare-up of sharply defined red patches, covered by a silvery, flaky surface. The main disease activity leading to psoriasis occurs in the epidermis, the top five layers of the skin. The disease most commonly appears on the skin of the scalp, elbow, knees, and lumboscaral areas of the body. Many of the patients are not receiving the appropriate treatment discussed in the current guidelines and standards of care. Psoriasis is a complex disease to manage, but the goal should be a patient-centered treatment that reduces disease burden, improves on quality-of-life, and addresses the risks of systemic complications and comorbid conditions. The under diagnosis and treatment of psoriasis continues to be a serious concern

Once psoriasis is diagnosed through a physical examination and a skin biopsy, treatment of the disease will depend on which type of psoriasis, where it is, and the severity of it. Newer biologics are more targeted to the inflammatory pathways involved in psoriasis, which works by blocking two proteins -- interleukin-17 and -23. These newer agents have been shown to be effective in treating psoriasis and could also be safer given their more specific action on the immune system. Treatments that inhibit IL-23 and IL-17 have shown promising data in safety and efficacy in clinical trials of moderate-to-severe psoriasis. Recent breakthroughs, and a better understanding of the pathogenesis of psoriasis, have been translated into targeted and highly effective therapies.These new options have shown improved efficacy and safety in psoriasis, and healthcare professionals must be educated on these agents and the potential risks that come along with any treatment option.

Upon completion of this activity, participants will be able to:

  • Analyze the etiology, pathophysiology, and diagnostic considerations of psoriasis

  • Develop a management plan, using the most recent guidelines, for newly diagnosed patients with psoriasis based on disease severity

  • Examine the safety and effectiveness of novel targeted treatments for psoriasis patients that have an inadequate response to conventional therapies

  • Develop new strategies to overcome different challenges of psoriasis, including adverse effects of novel therapies, patient adherence and managing comorbidities

  • Explore the role of a multidisciplinary care team, using shared decision-making strategies, to guide treatment choices and measurable goals to improve outcomes

  • Transform therapeutic advances and resource utilization data into informed health plan decisions and formulary discussions for managed care professionals

     

Faculty: April W Armstrong, MD, MPH
Associate Dean and Director of Clinical Research
Southern California Clinical and Translational Science Institute (CTSI)
Director of Psoriasis Program, Department of Dermatology
University of Southern California Keck School of Medicine

Disclosure:

Dr. Armstrong serves as a consultant for Abbvie, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, Leo Pharma Modernizing Medicine, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, and Sun Pharma. She has received grants or research from Abbvie, Bristol-Myers Squibb, Dermira, Eli Lilly, Janssen, Kyowa Hakko Kirin, Leo Pharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, and UCB Biopharma. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
AbbVie

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue